Endpoints News1h
Talk­space is us­ing AI to make ther­a­py pod­casts for pa­tients
Talkspace is using AI to make mini podcast episodes from patients’ therapy sessions. The “Talkcast” episodes are meant to be ...
Endpoints News1h
Break­ing: Fir­ings sweep across FDA, gut­ting lead­er­ship and whole of­fices
Mass firings and forced resignations swept through the FDA on Tuesday, as part of thousands of planned job cuts at federal ...
Endpoints News2h
Lil­ly claims Phase 2 win for siR­NA ap­proach to mixed dys­lipi­demia
Eli Lilly's RNA drug solbinsiran reduced ApoB protein levels by 14.3% in Phase 2 cholesterol trial, competing with ...
Endpoints News2h
RNA edit­ing start­up rais­es $155M to bring liv­er and lung dis­ease ther­a­py in­to clin­ic
When the transatlantic startup AIRNA launched in 2023, it was already years behind other companies that were trying to bring ...
Endpoints News2h
Sanofi con­tin­ues its bet on R&D by poach­ing GSK’s head of de­vel­op­ment
Sanofi hires former GSK development head Chris Corsico as global R&D head, replacing Dietmar Berger who left for Gilead. Move ...
Endpoints News17h
Tenaya to lay off about one-third of staff, re­veals heart gene ther­a­py da­ta
Heart gene therapy maker Tenaya Therapeutics is laying off 30% to 40% of its staff by the end of the year, the company’s CEO ...
Endpoints News16h
Fed­er­al judge nix­es FDA's lab-de­vel­oped test rule, says it ex­ceed­ed agen­cy's au­thor­i­ty
The FDA overstepped its authority when it issued a rule last May to bring laboratory-developed tests under the agency’s ...
Endpoints News18h
Vax­cyte's Phase 2 pneu­mo­coc­cal vac­cine da­ta dis­ap­point Wall Street
Vaxcyte’s stock price dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an ...
Endpoints News21h
As­traZeneca’s cho­les­terol pill is set for Phase 3, but lags be­hind Mer­ck ri­val
As­traZeneca has great am­bi­tions for its mid-stage oral cho­les­terol drug, be­liev­ing that it could reach peak sales of ...
Endpoints News21h
Marks’ ex­it at FDA rat­tles an al­ready tee­ter­ing biotech in­dus­try
FDA biologics chief Peter Marks resigns over vaccine dispute with HHS Secretary RFK Jr., causing biotech stocks to drop.
Endpoints News21h
Lil­ly's heart dis­ease drug could be dosed as lit­tle as once a year, study shows
Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could be dosed far less frequently than competing ...
Endpoints News22h
In­spir­na, which was prepar­ing for a Phase 3 can­cer tri­al, has fold­ed
A New York City drug developer led by well-known executives and backed by some of the top names in biotech investing is ...